{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:35Z","timestamp":1760188835312},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T00:00:00Z","timestamp":1134086400000},"content-version":"vor","delay-in-days":3875,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[1995,5]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:italic>. To determine if patients with rheumatoid arthritis (RA) that is stable with weekly methotrexate (MTX) therapy could be switched to an every\u2010other\u2010week regimen of MTX.<\/jats:p>Methods<\/jats:italic>. Forty\u2010seven patients with classic or definite RA who had received MTX for at least 8 months were studied. Clinical measurements consisted of the number of tender and swollen joints, physician and patient global evaluation of disease activity on a 5\u2010point scale, grip strength, patient evaluation of pain, morning stiffness, and the interval to onset of fatigue from time of awakening. Laboratory measures included the erythrocyte sedimentation rate (ESR), rheumatoid factor, C\u2010reactive protein (CRP), and baseline serum folate levels. Uptake of MTX was measured with tritiated thymidine from peripheral blood mononuclear cells (PBMC) from patients ex vivo. Serum measures of interleukin\u20101\u03b2 (IL\u20101\u03b2), IL\u20106, and tumor necrosis factor \u03b1 (TNF\u03b1) were performed in sera, and TNF\u03b1 was also measured on PBMC supernatants.<\/jats:p>Results<\/jats:italic>. Twelve of the 23 patients receiving every\u2010other\u2010week MTX (52%) were able to complete 6 months of this treatment without experiencing a disease flare. Eleven of the 23 patients receiving every\u2010other\u2010week MTX (48%) withdrew from the study before completing 6 months of treatment, because of a flare. No significant differences in clinical or laboratory parameters were seen when the 24 patients receiving weekly MTX were compared with the 12 patients in the every\u2010other\u2010week MTX group who successfully completed 6 months of the study. None of the changes in serum cytokine levels were significantly different between the patients receiving MTX weekly versus those receiving it every other week, and changes in ESR and CRP did not differ between groups. Age, sex, RA disease duration, MTX weekly dose or duration, baseline joint counts, or serum folate status did not predict a flare. Tritiated MTX uptake did not differ between groups.<\/jats:p>Conclusion<\/jats:italic>. Some patients with RA that is stable on weekly dosing are able to change to every\u2010other\u2010week dosing without experiencing a flare in their disease activity.<\/jats:p>","DOI":"10.1002\/art.1780380504","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T01:39:56Z","timestamp":1171503596000},"page":"601-607","source":"Crossref","is-referenced-by-count":13,"title":["Every\u2010other\u2010week methotrexate in patients with rheumatoid arthritis"],"prefix":"10.1002","volume":"38","author":[{"given":"Joel M.","family":"Kremer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna M. S.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Rynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayle F.","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Mullaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198503283121303"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280702"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-489"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290702"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310203"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310501"},{"key":"e_1_2_1_8_2","first-page":"1628","article-title":"Adverse experience with methotrexate during 176 weeks of a long\u2010term prospective trial in patients with rheumatoid arthritis","volume":"17","author":"Furst DE","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_1_9_2","first-page":"994","article-title":"Termination of slow\u2010acting antirheumatic therapy in rheumatoid arthritis: a 14\u2010year prospective evaluation of 1017 consecutive starts","volume":"17","author":"Wolfe F","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350203"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350202"},{"issue":"9","key":"e_1_2_1_12_2","first-page":"S40","article-title":"Long\u2010term prospective sequential liver biopsies in patients with rheumatoid arthritis on weekly oral methotrexate (abstract)","volume":"33","author":"Kremer JM","year":"1990","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780321004"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370304"},{"key":"e_1_2_1_15_2","first-page":"175","article-title":"1958 revision of diagnostic criteria for rheumatoid arthritis","volume":"9","author":"Ropes MW","year":"1958","journal-title":"Bull Rheum Dis"},{"key":"e_1_2_1_16_2","first-page":"978","article-title":"Selective toxicity of a new lipophilic antifolate, BW301U for methotrexate\u2010resistant cells with reduced drug uptake","volume":"45","author":"Taylor IW","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5801.654"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.12.1330"},{"key":"e_1_2_1_19_2","first-page":"1148","article-title":"The effect of antirheumatic drugs on interleukin 1 activity and IL\u20101 and IL\u20101 inhibitor production by human monocytes","volume":"17","author":"Chang DM","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320403"},{"key":"e_1_2_1_21_2","first-page":"1678","article-title":"The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis","volume":"19","author":"Chang DM","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(88)90025-2"},{"issue":"9","key":"e_1_2_1_23_2","first-page":"S144","article-title":"Correlation of immune parameters with clinical and laboratory effects in a prospective cohort of patients with rheumatoid arthritis receiving methotrexate (abstract)","volume":"35","author":"Kremer JM","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"5","key":"e_1_2_1_24_2","first-page":"R37","article-title":"Methotrexate therapy causes a significant decrease in soluble interleukin 2 receptors in patients with rheumatoid arthritis (abstract)","volume":"34","author":"Kremer JM","year":"1991","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360807"},{"issue":"9","key":"e_1_2_1_26_2","first-page":"S77","article-title":"Methotrexate induces significant changes in IL\u20101, IL\u20102, IL\u20106 and IL\u20108 but not lymphocyte markers in patients with rheumatoid arthritis (abstract)","volume":"36","author":"Kremer JM","year":"1993","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370108"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780380504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780380504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T20:56:34Z","timestamp":1700772994000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780380504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,5]]}},"alternative-id":["10.1002\/art.1780380504"],"URL":"https:\/\/doi.org\/10.1002\/art.1780380504","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5]]}}}